AbbVie (ABBV) said Wednesday that the US Food and Drug Administration granted accelerated approval for Emrelis for treatment of patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression.
The drug is authorized for adults who have received a prior systemic therapy, according to the company.
AbbVie said the approval of Emrelis is based on overall response rate and duration of response and continued approval is conditional on clinical benefit verified in confirmatory trials.
Shares of the company were down 4.2% in recent trading.
Price: 179.84, Change: -8.16, Percent Change: -4.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.